Introduction
Increasing evidence suggests that lipid accumulation in the liver plays an important role in the pathogenesis of obesity, diabetes and cardiovascular disease [1] . In addition, fatty liver (i.e., hepatic steatosis) gives rise to more severe forms of nonalcoholic fatty liver disease (NAFLD), including steatohepatitis, fibrosis or hepatic cirrhosis [2] . NAFLD is an escalating health concern, and its prevalence is in the range of 15-30% in the general population. Its prevalence is as high as 70% in type 2 diabetic patients, in whom NAFLD is a risk factor for cardiovascular disease, independent of the metabolic syndrome and other classical risk factors [3 ] . There is thus considerable interest in nutritional and pharmacological agents that are able to reduce hepatic lipid accumulation. One approach that has considerable promise is the oral administration of phospholipid either as a nutraceutical or as a functional food. An increasing number of studies in experimental animals suggest that either synthetic phospholipids or naturally occurring phospholipid isolates might be of significant benefit. The aim of the present article is to review studies that describe the beneficial effects of dietary phospholipid on hepatic lipid metabolism and their potential to affect atherosclerosis and cardiovascular disease.
Phospholipid intake and digestion in humans
The normal dietary intake of phospholipid is 2-8 g per day, which represents 1-10% of total daily fat intake. The most common phospholipid in the diet is phosphatidylcholine (i.e., lecithin). Dietary phosphatidylcholine is almost completely absorbed (>90%) by the human intestine, and rapidly appears in the phosphatidylcholine of plasma lipoproteins and red blood cells [4] . Other phospholipids, such as phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol are also ingested, but in much smaller amounts. Sphingomyelin, better classified as a sphingolipid, but still a phosphorus-containing lipid, is ingested at a level of 0.3-0.4 g per day, being present in eggs, milk, meat and fish. Phosphatidylcholine in these foods usually contains palmitic, stearic, oleic, or linoleic acid. The fatty acid composition of phosphatidylcholine in the intestinal lumen is, however, different from dietary phosphatidylcholine, since the majority of luminal phosphatidylcholine is derived from the bile. The biliary pathway delivers approximately 12 g of phospholipid and 1.5 g of cholesterol to the intestinal lumen per day, which is at least four times more than that supplied by the diet.
Pancreatic phospholipase A2 (PLA2) is largely responsible for phosphatidylcholine hydrolysis, yielding fatty acid and lysophosphatidylcholine (lysoPC). Pancreatic PLA2 is secreted as an anionic zymogen and is activated in the small intestine by tryptic cleavage of an N-terminal heptapeptide. It has a molecular weight of approximately 14 kDa and requires calcium for activation and the presence of bile salts for its activity. As described in an excellent review [5 ] , dietary sphingomyelin is hydrolyzed by intestinal alkaline sphingomyelinase and neutral ceramidase to sphingosine, which is absorbed and converted to palmitic acid. Once absorbed by the intestinal epithelium, lysoPC is reacylated to form phosphatidylcholine or alternatively hydrolyzed to form glycerol-3-phosphorylcholine. Liberated fatty acids are used for triglyceride synthesis. This triglyceride, together with reacylated phosphatidylcholine, is then incorporated into chylomicrons for transport via the lymph into the blood circulation. It is possible that some dietary phospholipid is also incorporated directly into HDL by the intestine, based on evidence that human intestinal CaCo-2 cells secrete apoA-I-containing HDL-sized lipoproteins [6] , fat feeding stimulates rat intestinal HDL production [7] , and jejunal apoA-I synthesis can be regulated by dietary phosphatidylcholine in newborn swine [8] . Thus, either by direct or indirect means, a major proportion of dietary phosphatidylcholine finds its way quite rapidly into plasma HDL [4] .
Hepatoprotective effects of dietary phospholipids
A number of informative studies by Lieber et al. (reviewed in [9, 10] ) have provided evidence that dilinoleoylphosphatidylcholine (DLPC), the major phospholipid species (43-50%) in polyenylphosphatidylcholine (PPC) extracted from soybeans, is able to protect against liver damage associated with excessive alcohol intake. In vitro, DLPC has a number of hepatoprotective properties including the ability to reduce alcohol-induced hepatocyte apoptosis, cytochrome P450IIE1 (CYP2E1) induction, mitochondrial respiratory dysfunction, and TNF-a generation by Kupffer cells. In addition to reducing lipid peroxidation and oxidative stress, DLPC inhibits hepatic fibrosis, by affecting hepatic stellate cell proliferation and collagen accumulation [9, 10] . Soybean PPC also reduces hyperlipidemia and fatty liver in rats given excess alcohol, an effect associated with improved hepatic fatty acid oxidation [11] .
Several investigators have described the effect of dietary phospholipid on hepatic steatosis in animals with nonalcoholic liver disease (as summarized in Table 1 [12] [13] [14] [15] [16] [17] [18] [19] 20 ]). Different manipulations have been used to induce steatosis in these experiments, such as administering a high-fat diet or supplementing diets with orotic acid. In some studies, animals with relatively normal livers were investigated, while in one study [20 ] , rats with a genetic predisposition to obesity and fatty liver disease were used. In all of these studies, dietary phospholipids (derived from safflowers, soybeans, egg or fish roe) were found to consistently lower plasma or hepatic lipid levels. The magnitude of reduction in hepatic lipid levels has been quite striking. For example, in hypercholesterolemic rabbits, dietary PPC reduced total liver cholesterol by 42% and liver triglyceride by 28% [17] . In orotic acid-fed rats, dietary phosphatidylcholine reduced hepatic triglyceride by 45% [19] . In hyperlipidemic rats with alcohol-induced fatty liver, PPC reduced liver triglyceride and cholesterol by 40% and 45%, respectively [11] . Hepatic lipid-lowering has generally been achieved with phospholipid added to the diet at levels varying from 2 to 6% by weight (Table 1) .
Mechanisms responsible for the reduction in hepatic lipid by dietary phospholipid
The antisteatotic effect of dietary phospholipid has often been found to be associated with a decrease in hepatic fatty acid synthesis and in some cases an increase in fatty acid oxidation (Table 1 ). In addition, an increase in faecal neutral steroid excretion has been observed, providing a mechanistic explanation for the reduction of cholesterol ester in the liver of phospholipid-supplemented animals. Egg phosphatidylcholine and egg sphingomyelin have both been shown to inhibit the intestinal absorption of cholesterol [21, 22] . At first glance, this might seem a little paradoxical, considering that phosphatidylcholine plays an important role in intestinal lipid absorption by enhancing micellar lipid solubility and providing surface material for the formation of intestinal lipoproteins (i.e., chylomicrons and HDL). One can speculate, however, that an excess of phospholipid in the gut lumen may lead to the formation of oversized or inappropriately formed lipid micelles that are not optimally processed by luminal enzymes or that are impeded from crossing the unstirred water layer. Reduced absorption of dietary lipids or reduced reabsorption of biliary lipids would thus lead to a reduction in liver lipid levels and amelioration of steatosis.
Interestingly, Duivenvoorden et al. [23 ] recently demonstrated that egg sphingomyelin (at dietary concentrations of 0.2% and 0.4% by weight) can dose-dependently lower plasma cholesterol and triglyceride levels in APOEÃ3 Leiden mice fed a Western-type diet. Other sphingolipids, which were not phospholipids, such as phytosphingosine, sphingosine, sphinganine, ceramide and cerebroside, also lowered plasma lipid levels. Dietary phytosphingosine (1% by weight) reduced hepatic steatosis by 50-60%. Dietary sphingolipids and phospholipids may or may not affect hepatic lipid metabolism by the same mechanism, but it is interesting to note that dietary phytosphingosine can also inhibit the intestinal absorption of both cholesterol and triglyceride [23 ] .
Other work has suggested that dietary phospholipid can stimulate biliary lipid secretion. In a recent study, Lamireau et al. [24 ] , investigated mice with homozygous disruption of the ABCB4 gene. These animals (given dietary supplementation with cholic acid), are a model for human Abcb4 deficiency, a hereditary cholestatic liver disease that leads to hepatic fibrosis and cirrhosis. Mice lacking Abcb4 are unable to transfer phosphatidylcholine from the inner to the outer leaflet of the canalicular membrane and are unable to secrete phospholipids into bile. When fed diets containing 20% by weight lecithin granules (i.e., 4.4% phospholipid-containing diets), cholic acid-supplemented animals were protected against hepatic fibrosis and cholestatic disease. Phospholipid-feeding in control and Abcb4À/À animals was associated with increased bile flow and increased secretion of bile acids and cholesterol, providing evidence of hepatoprotection through stimulation of biliary lipid output.
Phospholipid structure and hepatoprotection
An important question that remains to be answered regarding the hepatoprotective effects of dietary phospholipids is the extent to which their lipid-lowering activity is dependent on their chemical structure. In other words, to what extent is their hypolipidemic activity a function of the type of fatty acids attached at the 1 and 2 positions of the glycerol backbone or to what extent is it dependent on the type of charged head-group. Evidence to date seems to suggest that both fatty acid composition and head-group arrangement play an important role. For example, Shirouchi et al. [20 ] recently carried out experiments in Otsuka Long-Evans Tokushima fatty (OLETF) rats. These animals are hyperphagic, due to a lack of cholecystokinin receptors, and therefore become obese, with concomitant hyperlipidemia, diabetes and fatty liver. OLETF rats were fed 5% corn oil-containing semisynthetic diets, which also contained either 2% (by weight) egg phosphatidylcholine or 2% v3-phosphatidylcholine (derived from fish roe). The egg phosphatidylcholine contained 29.9% palmitic acid (16 : 0), 17.5% stearic acid (18 : 0), 21.0% oleic acid (18 : 1) and 15.4% linoleic acid (18 : 2), in comparison to the v3-phosphatidylcholine which contained 15.0%, 13.9%, 10.5% and 0.7% respectively. The v3-phosphatidylcholine also contained 12.0%, 5.2% and 28.1% of 20 : 5v3, 22 : 5v3 22: 6v3, which were not detected in the egg-phosphatidylcholine. After 4 weeks of feeding, the v3-phosphatidylcholine diet significantly reduced liver weight and hepatic triglyceride levels compared with the egg-phosphatidylcholine diet. The v3-phosphatidylcholine diet also lowered serum cholesterol and glucose levels, and increased serum adiponectin. These results clearly demonstrate that the fatty acid composition of dietary phosphatidylcholine is an important determinant of its ability to lower plasma and liver lipid levels.
Other studies, however, point to the fact that lipidlowering effects are independent of fatty acid composition. For example, in the work of Navder et al. [11] , rats with alcohol-induced fatty liver and hyperlipidemia were given PPC. They were compared with control animals given the same amount of linoleate (as safflower oil) and choline (as bitartrate salt). Beneficial effects were observed on hepatomegaly and hepatic lipid accumulation in PPCfed rather than control animals, supporting the concept that choline structurally attached to the dietary phospholipid is an important factor. A second example is provided by the work of Buang et al. [19] . In these experiments, carried out in Sprague-Dawley rats with orotic acidinduced fatty liver, the effect of dietary phosphatidylcholine was compared with that of dietary triglyceride having a very similar fatty acid profile. The S:M:P ratio was 16:19:63 for the phosphatidylcholine diet and 15:20:64 for the triglyceride diet. The phosphatidylcholine diet attenuated liver triglyceride accumulation by 45% compared to the triglyceride diet, providing evidence of a fatty acid-independent effect of the dietary phosphatidylcholine. At the same time, the lipid-lowering effect of phospholipid in the diet is not simply a function of the amount of phosphatidylcholine present, as supported by the early work of Imaizumi et al. [12] , in which synthetically prepared phosphatidylethanolamine at a level of 2% in the diet of Wistar rats had both plasma and liver lipidlowering activity. Phosphatidylcholine and phosphatidylethanolamine are asymmetrically distributed in the plasma membrane, with the majority of phosphatidylcholine being associated with the outer leaflet and the majority of phosphatidylethanolamine being in the inner leaflet. Li et al. [25 ] have provided very interesting evidence that manipulation of phosphatidylcholine/ phosphatidylethanolamine levels in mice leads to significant changes in cell membrane integrity, which in turn affects the progression of steatosis into steatohepatitis.
Dietary phospholipid and atherosclerosis
The aforementioned studies provide indirect evidence that dietary phospholipid, through beneficial effects on plasma and liver lipid metabolism, may protect against the development of atherosclerosis. Only a few studies, however, have drawn a direct link between dietary phospholipid and the inhibition of atherogenesis. In the first of these, O'Brien and Corrigan [26] fed soybean and egg lecithin (7.5% for 6 weeks) to guinea pigs with dietinduced hypercholesterolemia (i.e., 15% lard and 0.5% cholesterol diet). Soybean lecithin decreased total plasma cholesterol by 51% without decreasing HDL-cholesterol, while egg lecithin increased HDL-cholesterol by 177% without increasing total plasma cholesterol. Aortic cholesterol was significantly reduced (by 41%) in soybean lecithin-fed animals. A similar reduction was not observed, however, in the egg lecithin-fed animals.
Wilson et al. [27] fed three modified nonpurified diets to hamsters for 8 weeks: a hypercholesterolemic diet (HCD; 10% coconut oil þ 0.05% cholesterol), a soy lecithin HCD (HCDþSL, 3.4% soy lecithin containing 40% phosphatidylcholine, 35% phosphatidylethanolamine and 25% phosphatidylinositol), and an HCD with added linoleate and choline (HCD-SL). The HCD-SL diet reduced plasma triglyceride, cholesterol and non-HDL-cholesterol by 43, 37 and 47%, while the HCDþSL diet reduced these parameters to a significantly greater extent, 54, 58 and 73%, respectively. Aortic fatty streak area was in turn significantly lower in HCDþSL compared with HCD-SL-fed animals (À90% versus À49%, P < 0.001). These results show that a mixture of soy phospholipids added to the diet of hypercholesterolemic hamsters can reduce atherosclerosis, and this effect is not entirely dependent on the presence of linoleate or choline.
More recently, Navab et al. [28] carried out experiments in apoE-deficient mice, which were given either soy or egg lecithin in their drinking water (1.0 mg/ml), or alternatively, a similar concentration of the synthetic phospholipid, dimyristoylphosphatidylcholine (DMPC). Animals given DMPC (though not soy or egg lecithin) had significantly increased levels of plasma HDL-cholesterol and apoA-I, increased levels of jejunal apoA-I synthesis, and significantly reduced aortic sinus lesion area and en face whole aortic lesion area. Although it is unclear why DMPC, but not the other two natural phospholipid preparations, had antiatherogenic effects, these data suggest that certain types of phospholipid can inhibit atherosclerosis in animals with genetically dependent cardiovascular disease.
Dietary phospholipids in humans
Increasing evidence exists (as reviewed above) to support the concept that dietary phospholipid has beneficial effects on liver and plasma lipid metabolism in experimental animals. Only limited evidence is available, however, to suggest that dietary phospholipid supplementation is of benefit in humans. Several years ago, Knuiman et al. [29] scrutinized 24 studies on the effect of dietary lecithin (ranging from 1 to 54 g per day), in order to establish whether the consumption of lecithin had a more beneficial effect on serum cholesterol levels than equivalent amounts of polyunsaturated triglyceride. They concluded that there was no evidence for a specific effect of lecithin on serum cholesterol levels independent of its linoleic acid content.
More recently, there has been a focus on the ability of oral phospholipid to affect plasma HDL levels. Klimov et al. [30] treated 50 combined hyperlipidemic patients with purified phospholipid from soybeans (Lipostabil 300 forte, 1.8 g/day for 6 months). In this nonplacebocontrolled trial, phospholipid treatment resulted in significant reductions in total cholesterol, triglyceride and LDL-cholesterol, in association with a significant 12% increase in plasma HDL-cholesterol. Bunea et al. [31] investigated the effect of krill oil (1-3 g/day for 3 months) on plasma lipids in patients with hyperlipidemia. Krill oil is extracted from Antarctic krill and is rich in phospholipids containing long-chain v-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid). It also contains various antioxidants including vitamin A, vitamin E, and the carotenoid, astaxanthin. A remarkable dose-dependent 44-60% increase was observed in HDL-cholesterol levels, in association with favourable reductions in plasma cholesterol, triglyceride and LDLcholesterol [31] . In a much smaller study, Burgess et al. treated 16 normolipidemic individuals with phosphatidylinositol at a dose of either 2.8 or 5.6 g per day. The low dose resulted in a 13% increase in HDL-cholesterol, whereas the higher dose caused an increase of 18% over the 2-week treatment period [32] . Together, these results are interesting, but larger and better-controlled studies are clearly needed in order to define the extent to which different phospholipid preparations are able to beneficially affect plasma lipid and lipoprotein levels. It also remains to be seen whether dietary or dose-administered phospholipid can reduce hepatic lipid levels in human subjects.
Conclusion
In view of recent problems with drugs designed to treat the metabolic syndrome and prevent cardiovascular disease [33] , the concept of using naturally occurring compounds as cardioprotective or hepatoprotective agents is very attractive. Targeting nutraceutical therapy against the accumulation of fat in the liver is a sound strategy, which has the potential to beneficially affect plasma lipid levels and insulin sensitivity. As reviewed above, there is consistent experimental evidence to suggest that phospholipids from different sources have the potential to reduce hepatic lipid levels. Carefully controlled human trials are, however, required to substantiate the efficacy of this approach. It is also important that additional research be conducted to determine the extent to which certain phospholipids have the ability to affect plasma HDL levels and the development of cardiovascular disease. Future experiments will need to address such questions as which type of phospholipid (phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine or phosphatidylinositol) and what fatty acid composition (degree of saturation and chain length) is optimal for providing hepatoprotection? Do all phospholipids affect liver lipid metabolism in the same way and can this mode of action be targeted by synthetic phospholipids? To what extent do different dietary phospholipids affect plasma lipid and lipoprotein levels, particularly HDL? Which subject/patient groups are most likely to benefit from phospholipid therapy? What is the optimal dose and optimal route of administration of dietary phospholipid (i.e., as a nutraceutical in capsule form or as a functional food incorporated into food products)? And finally, should phospholipids be added to other active nutraceutical ingredients (e.g., flavonoids) to provide optimal benefit?
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